Novo Nordisk’s Defining Moment: Can a Pill Outweigh a Pipeline Setback?
The arithmetic of Novo Nordisk’s share price has become uncomfortably simple. At Monday’s close of 40.83 euros, the…
Novo Nordisk’s Earnings Reckoning: Options Traders Price In a Rare Double-Digit Swing
For a company that spent the better part of a year selling investors on a diversification story, Novo…
Novo Nordisk’s Russian Profit Surprise Masks a Growing Legal Headache
Novo Nordisk investors are digesting a curious paradox: the Danish drugmaker’s Russian subsidiary has more than quadrupled its…
Novo Nordisk’s Legal Blitz and Discounted Ozempic Copy Signal a New Phase in the GLP-1 Wars
The Danish pharmaceutical giant is firing on multiple fronts — in the courtroom, on the pricing front, and…
Novo Nordisk’s Two-Stage Catalyst: Earnings Due August 5 as CagriSema FDA Verdict Hovers
Novo Nordisk is entering a defining stretch of the year, with two pivotal events that could reshape the…
Novo Nordisk’s Pill Strategy Gets a Double Boost – EU Nod and Analyst Upgrade – Yet the Growth S
Novo Nordisk shares have recouped more than 40% from their early-March low, but the stock still sits nearly…
Fangzhou Launches Novo Nordisk’s Once-Weekly Basal Insulin/GLP-1 Therapy in China
SHANGHAI, July 20, 2026 (GLOBE NEWSWIRE) — Fangzhou Inc. (“Fangzhou” or the “Company”) (HKEX: 06086), a leading provider…
Novo Nordisk’s Oral Wegovy Wins EU Approval, but a Strict Dosing Regimen and Mounting Rivalry Chec
The European Commission’s green light for Novo Nordisk’s oral Wegovy tablet on 15 July 2026 marks the first…
Novo Nordisk’s Oral Wegovy Wins EU Approval – So Why Isn’t the Market Celebrating?
Novo Nordisk finally has what it has been fighting for: European regulators have cleared the oral version of…
Novo Nordisk’s Oral Wegovy Wins EU Nod: Can the Pill’s US Success Scale Across 27 Markets?
For millions of Europeans who have shunned weight-loss injections, the arrival of a daily pill could change the…
Wegovy Pill Wins EU Approval, Yet Novo Nordisk’s Rally Faces a Jittery Wait for FDA and Earnings
The European Commission has handed Novo Nordisk a clear edge in the race to dominate the oral weight?loss…
Novo Nordisk’s Rally Meets a Revenue Reckoning: Buyback Momentum Clashes with 2026 Guidance
Novo Nordisk has staged a striking recovery over the past month, with the stock climbing 17% even as…